The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Factors to consider when choosing between cilta-cel and ide-cel for R/R multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, considers important factors that should be addressed when deciding between ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) CAR T-cell therapy for patients with relapsed/refractory (R/R) multiple myeloma (MM). While both have the potential for achieving treatment-free remission, ide-cel is currently more accessible and associated with fewer toxicities. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
